Biogen and Eisai seek UK’s marketing authorisation for lecanemab
Pharmaceutical Technology
MAY 22, 2023
Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody that will be used to treat mild cognitive impairment caused due to AD and mild AD dementia in people with the confirmed presence of amyloid pathology in the brain. The regulator has also designated the therapy for the innovative licensing and access pathway (ILAP).
Let's personalize your content